Pennsylvania legislation · 2025-2026 Regular Session
Pennsylvania HB2749: An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for drug overdose medication.
Status: In committee, August 25, 2026
What the bill says
An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for drug overdose medication.
From the introduced text, August 25, 2026:
An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for drug overdose medication. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 13.8(e), (f) and (h) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, are amended and the section is amended by adding a subsection to read: Section 13.8. Drug Overdose Medication.--* * * (e) (1) A licensed health care professional who, acting in good faith, prescribes or dispenses an opioid antagonist or an expired opioid antagonist shall not be subject to any criminal or civil liability or any professional disciplinary action for: (i) such prescribing or dispensing; or (ii) any outcomes resulting from the eventual administration of the opioid antagonist. (2) The immunity under paragraph (1) shall not apply to a health professional who acts with intent to harm or with reckless indifference to a substantial risk of harm. …